{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:07:37Z","timestamp":1794485257751,"version":"4.9.1"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2025.102819","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:26:36Z","timestamp":1767025596000},"page":"102819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress"],"prefix":"10.1016","volume":"37","author":[{"given":"Nadezhda A.","family":"Pechnikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zafeiriou-Chatziefraimidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malamati","family":"Poimenidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysi","family":"Patsidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Iliadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia V.","family":"Ostankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-5214","authenticated-orcid":false,"given":"Alexey V.","family":"Yaremenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102819_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1126\/science.abi5658","article-title":"Ten millennia of hepatitis B virus evolution","volume":"374","author":"Kocher","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102819_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5005\/jp-journals-10018-1326","article-title":"Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine","volume":"10","author":"Laugi","year":"2020","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"10.1016\/j.omtn.2025.102819_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000162","article-title":"Global HBV disease burden and current care gaps","volume":"23","author":"Razavi-Shearer","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41575-024-00963-8","article-title":"Viral hepatitis elimination \u2014 time to act","volume":"21","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102819_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib8","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2025.102819_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2025.102819_bib10","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1038\/s41598-021-00455-8","article-title":"Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B","volume":"11","author":"Argirion","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B Virus-Associated Hepatocellular Carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102819_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2025.102819_bib13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S2468-1253(17)30217-0","article-title":"Peg-interferon plus nucleotide analogue in patients with chronic hepatitis B with low viral load","volume":"2","author":"Jindal","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/jpm13060964","article-title":"Current Therapy of Chronic Viral Hepatitis B, C and D","volume":"13","author":"Schlaak","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/liv.12409","article-title":"A brief history of hepatitis milestones","volume":"34","author":"Trepo","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.omtn.2025.102819_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2010.11.018","article-title":"Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome","volume":"55","author":"Seto","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","article-title":"Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir","volume":"113","author":"Shin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.omtn.2025.102819_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral Drug Resistance: Mechanisms and Clinical Implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.omtn.2025.102819_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.omtn.2025.102819_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101425","article-title":"Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases","volume":"48","author":"Wang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omtn.2025.102819_bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2025.102819_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11051140","article-title":"Vertical Transmission of Hepatitis B Virus\u2014An Update","volume":"11","author":"di Filippo Villa","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.omtn.2025.102819_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12575-025-00269-2","article-title":"Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses","author":"Albadr","year":"2025","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.omtn.2025.102819_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","article-title":"A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression","author":"Zhao","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omtn.2025.102819_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102819_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne","year":"2016","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.omtn.2025.102819_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib33","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/v13061124","article-title":"Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis","volume":"13","author":"Inoue","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102819_bib34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","article-title":"Structural insights into the HBV receptor and bile acid transporter NTCP","volume":"606","author":"Park","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102819_bib35","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/cells9061486","article-title":"Hepatitis B Virus Entry into Cells","volume":"9","author":"Herrscher","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102819_bib36","doi-asserted-by":"crossref","first-page":"42952","DOI":"10.18632\/oncotarget.5518","article-title":"Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk","volume":"6","author":"Jing","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102819_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01929-23","article-title":"Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions","volume":"98","author":"Zhang","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102819_bib38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.adp1453","article-title":"Inherent symmetry and flexibility in hepatitis B virus subviral particles","volume":"385","author":"Wang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102819_bib39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00705-010-0657-5","article-title":"Fibronectin and asialoglyprotein receptor mediate hepatitis B surface antigen binding to the cell surface","volume":"155","author":"Yang","year":"2010","journal-title":"Arch. Virol."},{"key":"10.1016\/j.omtn.2025.102819_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110184","article-title":"Exchanges in the \u2018a\u2019 determinant of the hepatitis B virus surface antigen revisited","volume":"599","author":"Pond\u00e9","year":"2024","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2025.102819_bib41","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1038\/s41598-025-89303-7","article-title":"The pattern change of hepatitis B virus genetic diversity in Northwestern Tanzania","volume":"15","author":"Mlewa","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib42","article-title":"Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-na\u00efve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study","volume":"12","author":"Hoang","year":"2025","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcmgh.2023.03.011","article-title":"Hepatitis B Virus Targets Lipid Transport Pathways to Infect Hepatocytes","volume":"16","author":"Esser","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib44","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102819_bib45","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102819_bib46","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102819_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and Tumor Necrosis Factor-\u03b1 Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2025.102819_bib48","series-title":"Zakim and Boyer\u2019s Hepatology","first-page":"1257","article-title":"Viral Hepatitis in Children","author":"Elisofon","year":"2012"},{"key":"10.1016\/j.omtn.2025.102819_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000156","article-title":"Management of chronic hepatitis B infection in children","volume":"23","author":"Chen","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bpg.2017.05.003","article-title":"Hepatitis B virus infection and the immune response: The big questions","volume":"31","author":"Boeijen","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.omtn.2025.102819_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(01)00172-4","article-title":"Immunology of hepatitis B infection","volume":"2","author":"Jung","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune responses to HCV and other hepatitis viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102819_bib54","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jvh.12216","article-title":"Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen","volume":"21","author":"Jiang","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.omtn.2025.102819_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of Hepatitis B Virus Persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omtn.2025.102819_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/atm.2017.01.28","article-title":"Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection","volume":"5","author":"Parikh","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2025.102819_bib59","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1499-3872(11)60084-2","article-title":"Collagen proportionate area of liver tissue determined by digital image analysis in patients with HBV-related decompensated cirrhosis","volume":"10","author":"Xie","year":"2011","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.omtn.2025.102819_bib61","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1007\/s10620-021-07009-y","article-title":"Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis","volume":"67","author":"Lin","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.omtn.2025.102819_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12710","article-title":"Reversibility of hepatitis B virus cirrhosis after therapy: Who and why?","volume":"35","author":"Bedossa","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.omtn.2025.102819_bib63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102819_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.livres.2024.05.004","article-title":"Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res."},{"key":"10.1016\/j.omtn.2025.102819_bib65","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0274","article-title":"Viral hepatitis and liver cancer","volume":"372","author":"Ringehan","year":"2017","journal-title":"Philos. Trans. R. Soc., B."},{"key":"10.1016\/j.omtn.2025.102819_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jhep.2016.09.013","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection","volume":"66","author":"Chayanupatkul","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2010.08.019","article-title":"Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma","volume":"9","author":"Yang","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib68","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.vaccine.2017.04.011","article-title":"Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation","volume":"35","author":"Breakwell","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102819_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.616023","article-title":"Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region","volume":"11","author":"Araujo","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omtn.2025.102819_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B","volume":"45","author":"Kumar","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2025.102819_bib72","article-title":"Pharmacological interventions for acute hepatitis B infection: An attempted network meta-analysis","volume":"3","author":"Mantzoukis","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omtn.2025.102819_bib73","doi-asserted-by":"crossref","first-page":"e00046-19","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: Advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omtn.2025.102819_bib74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.33073\/pjm-2020-044","article-title":"Hepatitis b virus: From diagnosis to treatment","volume":"69","author":"GUVENIR","year":"2020","journal-title":"Pol. J. Microbiol."},{"key":"10.1016\/j.omtn.2025.102819_bib75","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102819_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib77","series-title":"Zakim and Boyer\u2019s Hepatology","first-page":"540","article-title":"Hepatitis B","author":"Chan","year":"2012"},{"key":"10.1016\/j.omtn.2025.102819_bib78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2025.102819_bib79","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2025.102819_bib81","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.omtn.2025.102819_bib82","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib83","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2025.102819_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir\u2014A Propensity Score\u2013Matched Study","volume":"219","author":"Nguyen","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib85","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2025.102819_bib86","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/vaccines11121862","article-title":"HBV Vaccines: Advances and Development","volume":"11","author":"Mahmood","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102819_bib87","first-page":"S88","article-title":"LBP-022 Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B","volume":"80","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib88","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","article-title":"Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo","volume":"30","author":"Gorsuch","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib89","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/acsinfecdis.8b00223","article-title":"In Vivo Model Systems for Hepatitis B Virus Research","volume":"5","author":"Ortega-Prieto","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766534","article-title":"In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.06.012","article-title":"Modeling hepatitis B virus infection, immunopathology and therapy in mice","volume":"121","author":"Cheng","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtn.2025.102819_bib92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/vaccines12030237","article-title":"mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model","volume":"12","author":"De Pooter","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102819_bib94","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/pharmaceutics17020211","article-title":"A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane","volume":"17","author":"Liu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102819_bib95","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1016\/j.ymthe.2025.06.027","article-title":"mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models","volume":"33","author":"Limeres","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41392-024-02026-5","article-title":"Multiplexed RNAs in lipid nanoparticles: potential therapeutic vaccine for chronic hepatitis B","volume":"9","author":"Rachamala","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66876-5","article-title":"An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102819_bib98","unstructured":"Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B https:\/\/www.businesswire.com\/news\/home\/20250806619711\/en\/Precision-BioSciences-Announces-Phase-1-Safety-and-Efficacy-for-Cohort-1-Lowest-Dose-Level-in-ELIMINATE-B-a-First-In-Human-Trial-of-PBGENE-HBV-for-Chronic-Hepatitis-B."},{"key":"10.1016\/j.omtn.2025.102819_bib99","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i4.105797","article-title":"Drug development for chronic hepatitis B functional cure: Recent progress","volume":"17","author":"Liu","year":"2025","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib140","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102819_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2019.00031","article-title":"The Combination Vaccine Adjuvant System Alum\/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization","volume":"9","author":"Ebensen","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.omtn.2025.102819_bib142","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/17460794.2.5.421","article-title":"DNA vaccine: a promising new approach for chronic hepatitis B therapy","volume":"2","author":"Cova","year":"2007","journal-title":"Future Virol."},{"key":"10.1016\/j.omtn.2025.102819_bib143","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12985-018-1026-3","article-title":"Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates","volume":"15","author":"Zhang","year":"2018","journal-title":"Virol. J."},{"key":"10.1016\/j.omtn.2025.102819_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67797-x","article-title":"COMPARING vaccine manufacturing technologies recombinant DNA vs in vitro transcribed (IVT) mRNA","volume":"14","author":"Davidopoulou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omtn.2025.102819_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/21645515.2019.1689745","article-title":"Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance","volume":"16","author":"Whitacre","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtn.2025.102819_bib101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib102","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/vaccines10101644","article-title":"Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection","volume":"10","author":"Akbar","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102819_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13040389","article-title":"The Application of mRNA Technology for Vaccine Production\u2014Current State of Knowledge","volume":"13","author":"Paczkowska","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2025.102819_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.omtn.2025.102819_bib105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib106","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.3390\/cancers14235874","article-title":"DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtn.2025.102819_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102819_bib108","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.vaccine.2017.03.049","article-title":"Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials","volume":"35","author":"Lobaina","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102819_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115340","article-title":"A comprehensive comparison of DNA and RNA vaccines","volume":"210","author":"Wang","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102819_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102819_bib112","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbaf023","article-title":"Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues","volume":"12","author":"Wang","year":"2025","journal-title":"Regen. Biomater."},{"key":"10.1016\/j.omtn.2025.102819_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.omtn.2025.102819_bib114","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102819_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib116","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib117","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41596-025-01174-4","article-title":"The design, manufacture and LNP formulation of mRNA for research use","volume":"20","author":"Leighton","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102819_bib118","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2025.102819_bib119","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol","volume":"16","author":"Johansson","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102819_bib120","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/s41467-025-59501-y","article-title":"Structure-guided design of endosomolytic chloroquine-like lipid nanoparticles for mRNA delivery and genome editing","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102819_bib121","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/vaccines11020362","article-title":"Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology","volume":"11","author":"Hamedi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102819_bib122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination","volume":"9","author":"Buoninfante","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omtn.2025.102819_bib123","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11901-024-00662-7","article-title":"A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators","volume":"23","author":"Dossaji","year":"2024","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib124","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib125","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jvh.13843","article-title":"Cost-effectiveness of treating all hepatitis B\u2013positive individuals in the United States","volume":"30","author":"Razavi-Shearer","year":"2023","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.omtn.2025.102819_bib126","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib127","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102819_bib128","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202500114","article-title":"On-Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles","volume":"21","author":"Zilberzwige-Tal","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.omtn.2025.102819_bib129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.omtn.2025.102819_bib130","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102819_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105638","article-title":"Unlocking the potential of circular RNA vaccines: a bioinformatics and computational biology perspective","volume":"114","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtn.2025.102819_bib132","first-page":"1","article-title":"Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport","volume":"10","author":"Wojcechowskyj","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omtn.2025.102819_bib133","article-title":"Probiotics and their metabolite spermidine enhance IFN-\u03b3+CD4+ T cell immunity to inhibit hepatitis B virus","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtn.2025.102819_bib134","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102819_bib135","doi-asserted-by":"crossref","first-page":"41851","DOI":"10.1038\/srep41851","article-title":"Efficient genome replication of hepatitis B virus using adenovirus vector: A compact pregenomic RNA-expression unit","volume":"7","author":"Suzuki","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib136","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12985-025-02662-5","article-title":"Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector","volume":"22","author":"Mnyandu","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.omtn.2025.102819_bib137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11901-025-00710-w","article-title":"Strategies to Achieve Functional Cure in HBV: Focus on siRNA","volume":"24","author":"Karthikeyan","year":"2025","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.omtn.2025.102819_bib138","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181067","article-title":"A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses","volume":"9","author":"Hasanpourghadi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102819_bib139","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J. Hepatol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:13:47Z","timestamp":1780103627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253125003737"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102819","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102819"}}